{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:15:25Z","timestamp":1783329325707,"version":"3.54.6"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010612","name":"ChadTough Defeat DIPG Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"Saint Baldricks Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201196","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:16:44Z","timestamp":1775182604000},"page":"201196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities"],"prefix":"10.1016","volume":"34","author":[{"given":"Kun-Wei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal Preet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7445-3190","authenticated-orcid":false,"given":"Sneha","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201196_bib1","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/neuonc\/noaa295","article-title":"Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017","volume":"23","author":"Patil","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100861","article-title":"Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group","volume":"35","author":"Cooney","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201196_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MPH.0000000000000547","article-title":"Survival After Relapse of Medulloblastoma","volume":"38","author":"Koschmann","year":"2016","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201196_bib9","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201196_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14712598.2020.1738378","article-title":"Prospects and challenges for use of CAR T cell therapies in solid tumors","volume":"20","author":"Ramakrishna","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.omton.2026.201196_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201196_bib16","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201196_bib17","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201196_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201196_bib19","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.abo7649","article-title":"Transforming the understanding of brain immunity","volume":"380","author":"Castellani","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201196_bib22","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.omton.2026.201196_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omton.2026.201196_bib24","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201196_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1215\/15228517-2007-066","article-title":"Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma","volume":"10","author":"Joshi","year":"2008","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib27","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-3-38","article-title":"The natural history of EGFR and EGFRvIII in glioblastoma patients","volume":"3","author":"Heimberger","year":"2005","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201196_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4963","article-title":"Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201196_bib31","first-page":"4130","article-title":"Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII","volume":"57","author":"Wikstrand","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.669071","article-title":"Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma","volume":"11","author":"Durgin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"10.1016\/j.omton.2026.201196_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201196_bib35","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib37","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1093\/brain\/awab155","article-title":"Tumour immune landscape of paediatric high-grade gliomas","volume":"144","author":"Ross","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.omton.2026.201196_bib38","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/brain\/awab347","article-title":"Erratum to: Tumour immune landscape of paediatric high-grade gliomas","volume":"144","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.omton.2026.201196_bib39","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.1301966","article-title":"Characterization of distinct immunophenotypes across pediatric brain tumor types","volume":"191","author":"Griesinger","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201196_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/neuonc\/noy145","article-title":"Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy","volume":"21","author":"Lieberman","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib41","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib42","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor\u2013Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib43","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","article-title":"HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors","volume":"16","author":"Ahmed","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","article-title":"Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery","volume":"23","author":"Haydar","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib46","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201196_bib48","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201196_bib50","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005187","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201196_bib52","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201196_bib53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201196_bib54","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201196_bib56","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201196_bib57","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib58","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201196_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201196_bib60","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13073-025-01498-6","article-title":"The CXCL16\/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"17","author":"Lu","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.omton.2026.201196_bib62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib63","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib64","first-page":"148","article-title":"Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities","volume":"14","author":"Vitanza","year":"2024","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"10.1016\/j.omton.2026.201196_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201196_bib66","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201196_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004450","article-title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","volume":"10","author":"Foster","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201196_bib68","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib69","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-20-3241","article-title":"Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)","volume":"27","author":"Chen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib70","article-title":"Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1","author":"Gholamin","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omton.2026.201196_bib71","article-title":"Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R\u303f2-targeting CAR T cells: an interim analysis","author":"Wang","year":"2023","journal-title":"Res. Sq."},{"key":"10.1016\/j.omton.2026.201196_bib72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12974-024-03047-1","article-title":"Cryopreservation of c cells preserves the transcriptional landscape for single-cell analysis","volume":"21","author":"Kodali","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.omton.2026.201196_bib73","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201196_bib74","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201196_bib75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2026.201196_bib76","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201196_bib77","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2016.34.15_suppl.2067","article-title":"Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma","volume":"34","author":"O'Rourke","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201196_bib78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib79","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201196_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1137","article-title":"Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma","volume":"9","author":"Tang","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.omton.2026.201196_bib81","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201196_bib82","first-page":"1861","article-title":"Autologous Natural Killer Cell Therapy for Human Recurrent Malignant Glioma","volume":"24","author":"ISHIKAWA","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2026.201196_bib83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omton.2026.201196_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201196_bib85","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201196_bib86","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.4049\/jimmunol.2300729","article-title":"Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory Markers in a COVID-19 Cohort","volume":"212","author":"Abe","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201196_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax5851","article-title":"MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure","volume":"5","author":"Keren","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201196_bib88","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/s41596-021-00556-8","article-title":"CODEX multiplexed tissue imaging with DNA-conjugated antibodies","volume":"16","author":"Black","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omton.2026.201196_bib89","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1038\/s41467-023-43458-x","article-title":"High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis","volume":"14","author":"Janesick","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201196_bib90","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2026.201196_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27595","article-title":"Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies","volume":"66","author":"Abbou","year":"2019","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:20:57Z","timestamp":1783326057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992600072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S295032992600072X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201196","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201196"}}